zanubrutinib,ibrutinib
abbvie,janssen,beigene
['bet', ' ibru', 'zanubrutinib', 'lymphoma', 'lymsm']
interesting molecular correlates substudy suggests mzl patients with myd88 or tnfaip3 mutations are likely to do well when treated with zanubrutinib #ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer